Hepatitis C

;

Sens. Cassidy & Van Hollen introduce historic bill to eliminate hepatitis C

Jun 4, 2025

We deeply thank Chairman Cassidy and Senator Van Hollen for their bipartisan leadership and dedication to eliminating hepatitis C. It has been unacceptable that people with hepatitis C have had to overcome so many discriminatory barriers instituted by state Medicaid programs and insurers to access hepatitis C curative drugs over the past twelve years since the first drug was approved. Additionally, our government has failed to invest in the public health infrastructure needed to increase awareness, testing, and linkage to care and the curative drugs. This bill, if enacted, will finally provide the necessary resources to ensure that more people are diagnosed and linked to no-cost treatment so that we can eventually eliminate hepatitis C.

read more

Biden budget maintains domestic HIV funding & proposes PrEP & hepatitis C programs

Mar 11, 2024

“While we appreciate the proposed continued funding of  domestic HIV and hepatitis programs and acknowledge the legislatively imposed budget constraints and competing priorities, the reality is that, without serious increases, our nation cannot meet its goals to end the HIV and hepatitis epidemics on time,” commented Carl Schmid, Executive Director of the HIV+Hepatitis Policy Institute. “Now, we must take our case for any funding increases to Congress, which has found it difficult to agree on spending bills, and House Republicans have even proposed to cut domestic HIV spending this year by $767 million.”

read more

Nation must do better in ensuring patients receive hepatitis C curative drugs

Jun 29, 2023

“This situation is completely unacceptable. We have a cure for a serious infectious disease, but people who have taken the time to get tested and know they have hepatitis C are not being cured,” commented Carl Schmid, executive director of the HIV+Hepatitis Policy Institute. “The vast majority of these people have health coverage but payers such as private insurers, state Medicaid programs, and Medicare are erecting barriers to patient access by not covering medications or requiring cumbersome prior authorizations or imposing high patient cost-sharing. If the federal government is serious about ending hepatitis C, it needs to provide the leadership, particularly at CMS, and address these payer barriers.”

read more

25 HIV and Hepatitis organizations file amicus brief to protect preventive services coverage

Jun 23, 2023

The HIV+Hepatitis Policy Institute and 24 other HIV and hepatitis organizations filed an amicus brief in support of the U.S. government in Braidwood Management v. Becerra, the challenge to the ACA’s preventive services coverage requirement, arguing, “A wholesale invalidation of the coverage requirement for USPSTF’s recommendations would strike a critical, unnecessary, and costly blow to the battle to end HIV, hepatitis, and other infectious diseases.”

read more

Search

Press Release Tags

ACA Appropriations Biden administration CDC Congress Copay accumulators Copay assistance Cost-sharing COVID-19 Drug Pricing FDA Gay men healthcare Hepatitis Hepatitis B Hepatitis C hepatits HIV HIV Prevention hous housing insurer Insurers LGBT Medicaid Medicare Part D NAIC NIH PBMs PrEP Prescription Drugs prevention Private Insurance Ryan White Ryan White Program state Syringe services Testing transparency Treatment Trump administration

Recent Press Releases

Pin It on Pinterest